SUPN +23%Here we see a strong impulse and long correction during almost 2 years. Now it’s breakout and going higher.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.08 USD
1.32 M USD
607.52 M USD
52.88 M
About Supernus Pharmaceuticals, Inc.
Sector
CEO
Jack A. Khattar
Headquarters
Rockville
Website
Founded
2005
FIGI
BBG000BP0HX7
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
SUPN going upWhat used to be a resistance now a support.
Plus an inverse head & shoulders.
Plus positive news: “Supernus said that a Phase 3 trial 'met the primary endpoint ... compared to placebo in improving the symptoms of ADHD.'"
Going long anticipating 30’s where MA200 is and then maybe higher.
With tight s
$SUPN Supernus Pharmaceuticals Bull flag This share reports earnings today. Downtrend broken and building what looks like a bull flag. Targets 29.40 and 33 if this bull flag breaks to the upside.
SUPN LongMonthly trend change on wave trend indicator. 4 hour chart looks strong. VIX oversold signal screaming oversold. What's not to like?
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SUPN is 35.60 USD — it has increased by 0.03% in the past 24 hours. Watch Supernus Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Supernus Pharmaceuticals, Inc. stocks are traded under the ticker SUPN.
SUPN stock has fallen by −4.69% compared to the previous week, the month change is a −1.33% fall, over the last year Supernus Pharmaceuticals, Inc. has showed a 23.10% increase.
We've gathered analysts' opinions on Supernus Pharmaceuticals, Inc. future price: according to them, SUPN price has a max estimate of 43.00 USD and a min estimate of 36.00 USD. Watch SUPN chart and read a more detailed Supernus Pharmaceuticals, Inc. stock forecast: see what analysts think of Supernus Pharmaceuticals, Inc. and suggest that you do with its stocks.
SUPN reached its all-time high on Jun 29, 2018 with the price of 61.25 USD, and its all-time low was 4.30 USD and was reached on Jun 5, 2012. View more price dynamics on SUPN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SUPN stock is 2.47% volatile and has beta coefficient of 0.81. Track Supernus Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Supernus Pharmaceuticals, Inc. there?
Today Supernus Pharmaceuticals, Inc. has the market capitalization of 1.97 B, it has decreased by −1.74% over the last week.
Yes, you can track Supernus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Supernus Pharmaceuticals, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
SUPN earnings for the last quarter are 1.17 USD per share, whereas the estimation was 0.44 USD resulting in a 163.56% surprise. The estimated earnings for the next quarter are 0.50 USD per share. See more details about Supernus Pharmaceuticals, Inc. earnings.
Supernus Pharmaceuticals, Inc. revenue for the last quarter amounts to 175.69 M USD, despite the estimated figure of 157.35 M USD. In the next quarter, revenue is expected to reach 154.51 M USD.
SUPN net income for the last quarter is 38.50 M USD, while the quarter before that showed 19.92 M USD of net income which accounts for 93.30% change. Track more Supernus Pharmaceuticals, Inc. financial stats to get the full picture.
No, SUPN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 652.00 employees. See our rating of the largest employees — is Supernus Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Supernus Pharmaceuticals, Inc. EBITDA is 156.00 M USD, and current EBITDA margin is 16.17%. See more stats in Supernus Pharmaceuticals, Inc. financial statements.
Like other stocks, SUPN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Supernus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Supernus Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Supernus Pharmaceuticals, Inc. stock shows the buy signal. See more of Supernus Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.